Related Experiment Video

Updated: Feb 28, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.1K

The Structure, Pathogenesis, and Inhibition of the p53-MDM2 Pathway

Amanda L Brown1, Xiaoying Lian2, Qian Wang2

  • 1School of Medicine, University of South Carolina, Columbia, SC 29209, USA.

Cancers
|February 27, 2026
PubMed

Insights

Mouse double minute 2 (MDM2) inhibits the tumor suppressor p53. Inhibiting MDM2 shows promise for treating cancers with wild-type or mutant p53, with non-covalent inhibitors like AQ-101 demonstrating good efficacy and safety.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The p53 tumor suppressor is crucial for genomic stability, regulating cell cycle arrest, apoptosis, and DNA repair.
  • Mouse double minute 2 (MDM2) is an E3 ubiquitin ligase that negatively regulates p53 through binding and degradation.
  • MDM2 overexpression or amplification can drive tumorigenesis, even in cancers with wild-type p53.

Purpose of the Study:

  • To review the structural features of MDM2 and their role in p53 regulation.
  • To examine the pathological consequences of MDM2 dysregulation and cancer-associated SNPs.
  • To discuss recent advancements in small molecule MDM2 inhibitors for cancer therapy.

Main Methods:

  • Structural analysis of MDM2, focusing on the N-terminal hydrophobic pocket and C-terminal RING domain.
  • Review of literature on MDM2 dysregulation, single nucleotide polymorphisms (SNPs), and their link to cancer.
  • Examination of preclinical data for small molecule MDM2 inhibitors, particularly non-covalent agents.

Main Results:

  • MDM2's structure facilitates p53 inhibition; its dysregulation contributes to cancer development.
  • Specific MDM2 SNPs are associated with increased cancer susceptibility.
  • Non-covalent MDM2 inhibitors, such as rhein-derived AQ-101, exhibit potent anti-cancer activity and reduced toxicity.

Conclusions:

  • MDM2 is a critical regulator of p53, and its dysregulation is oncogenic.
  • Non-covalent MDM2 inhibitors represent a promising therapeutic strategy for various cancers.
  • Further development of these inhibitors could offer new treatment options for patients with wild-type or mutant p53 tumors.
Keywords:
MDM2 RING domainMDM2 inhibitionnon-covalent inhibitionp53rhein-derived compoundstargeted therapy

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

2.1K
Purification of Ubiquitinated p53 Proteins from Mammalian Cells10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

2.8K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.4K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.2K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.3K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.9K